Lenalidomide is widely used for multiple myeloma (MM); however, while it is effective, most patients relapse and become lenalidomide-refractory. In this interview, conducted at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the objectives of the OPTIMISMM trial (NCT01734928), which investigates the efficacy of the triplet regimen of pomalidomide, bortezomib and dexamethasone against the doublet of bortezomib and dexamethasone. Dr Richardson mentions some of the preliminary results that have been obtained, before speaking about the future potential for the regimen.
OPTIMISMM: investigating an alternative therapy for lenalidomide-refractory patients
